AIMS: Phosphatase and tensin homolog (PTEN) is implicated as a negative regulator of vascular smooth muscle cell (SMC) proliferation and injury-induced vascular remodelling. We tested if selective depletion of PTEN only in SMC is sufficient to promote SMC phenotypic modulation, cytokine production, and enhanced neointima formation. METHODS AND RESULTS: Smooth muscle marker expression and induction of pro-inflammatory cytokines were compared in cultured SMC expressing control or PTEN-specific shRNA. Compared with controls, PTEN-deficient SMC exhibited increased phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signalling and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) activity, reduced expression of SM markers (SM-alpha-actin and calponin), and increased production of stromal cell-derived factor-1alpha (SDF-1alpha), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), and chemokine (C-X-C motif) ligand 1 (KC/CXCL1) under basal conditions. PI3K/Akt or mTOR inhibition reversed repression of SM marker expression, whereas PI3K/Akt or NF-kappaB inhibition blocked cytokine induction mediated by PTEN depletion. Carotid ligation in mice with genetic reduction of PTEN specifically in SMC (SMC-specific PTEN heterozygotes) resulted in enhanced neointima formation, increased SMC hyperplasia, reduced SM-alpha-actin and calponin expression, and increased NF-kappaB and cytokine expression compared with wild-types. Lesion formation in SMC-specific heterozygotes was similar to lesion formation in global PTEN heterozygotes, indicating that inactivation of PTEN exclusively in SMC is sufficient to induce considerable increases in neointima formation. CONCLUSION: PTEN activation specifically in SMC is a common upstream regulator of multiple downstream events involved in pathological vascular remodelling, including proliferation, de-differentiation, and production of multiple cytokines.
AIMS: Phosphatase and tensin homolog (PTEN) is implicated as a negative regulator of vascular smooth muscle cell (SMC) proliferation and injury-induced vascular remodelling. We tested if selective depletion of PTEN only in SMC is sufficient to promote SMC phenotypic modulation, cytokine production, and enhanced neointima formation. METHODS AND RESULTS: Smooth muscle marker expression and induction of pro-inflammatory cytokines were compared in cultured SMC expressing control or PTEN-specific shRNA. Compared with controls, PTEN-deficient SMC exhibited increased phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signalling and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) activity, reduced expression of SM markers (SM-alpha-actin and calponin), and increased production of stromal cell-derived factor-1alpha (SDF-1alpha), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), and chemokine (C-X-C motif) ligand 1 (KC/CXCL1) under basal conditions. PI3K/Akt or mTOR inhibition reversed repression of SM marker expression, whereas PI3K/Akt or NF-kappaB inhibition blocked cytokine induction mediated by PTEN depletion. Carotid ligation in mice with genetic reduction of PTEN specifically in SMC (SMC-specific PTEN heterozygotes) resulted in enhanced neointima formation, increased SMC hyperplasia, reduced SM-alpha-actin and calponin expression, and increased NF-kappaB and cytokine expression compared with wild-types. Lesion formation in SMC-specific heterozygotes was similar to lesion formation in global PTEN heterozygotes, indicating that inactivation of PTEN exclusively in SMC is sufficient to induce considerable increases in neointima formation. CONCLUSION:PTEN activation specifically in SMC is a common upstream regulator of multiple downstream events involved in pathological vascular remodelling, including proliferation, de-differentiation, and production of multiple cytokines.
Authors: Peter M Mourani; Pamela J Garl; Janet M Wenzlau; Todd C Carpenter; Kurt R Stenmark; Mary C M Weiser-Evans Journal: Circulation Date: 2004-03-01 Impact factor: 29.690
Authors: Ute Zeiffer; Andreas Schober; Michael Lietz; Elisa A Liehn; Wolfgang Erl; Neil Emans; Zhong-qun Yan; Christian Weber Journal: Circ Res Date: 2004-02-12 Impact factor: 17.367
Authors: Kathleen A Martin; Eva M Rzucidlo; Bethany L Merenick; Diane C Fingar; David J Brown; Robert J Wagner; Richard J Powell Journal: Am J Physiol Cell Physiol Date: 2003-10-30 Impact factor: 4.249
Authors: Pamela J Garl; Janet M Wenzlau; Heather A Walker; John M Whitelock; Mercedes Costell; Mary C M Weiser-Evans Journal: Circ Res Date: 2003-12-01 Impact factor: 17.367
Authors: Kyle C Kurek; Emily Howard; L B Tennant; Joseph Upton; Ahmad I Alomari; Patricia E Burrows; Kim Chalache; David J Harris; Cameron C Trenor; Charis Eng; Steven J Fishman; John B Mulliken; Antonio R Perez-Atayde; Harry P W Kozakewich Journal: Am J Surg Pathol Date: 2012-05 Impact factor: 6.394
Authors: Fatima Z Saddouk; Li-Yan Sun; Yong Feng Liu; Miao Jiang; Diane V Singer; Johannes Backs; Dee Van Riper; Roman Ginnan; John J Schwarz; Harold A Singer Journal: FASEB J Date: 2015-11-13 Impact factor: 5.191
Authors: Henrick N Horita; Peter A Simpson; Allison Ostriker; Seth Furgeson; Vicki Van Putten; Mary C M Weiser-Evans; Raphael A Nemenoff Journal: Arterioscler Thromb Vasc Biol Date: 2011-09-22 Impact factor: 8.311
Authors: Yazhini Ravi; Karuppaiyah Selvendiran; Shan K Naidu; Sarath Meduru; Lucas A Citro; Balázs Bognár; Mahmood Khan; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy; Chittoor B Sai-Sudhakar Journal: Hypertension Date: 2013-01-21 Impact factor: 10.190